Boston Scientific reaffirms renal denervation commitment; Ariad and Medinol begin stent trial;

@FierceMedDev: Covidien's ventilator recall gets hit with FDA's 'most serious' Class I label. More | Follow @FierceMedDev

@MarkHFierce: The latest weekly edition of FierceDiagnostics is all ready for you, now with added biomarker coverage. Check it out. Issue | Follow @MarkHFierce

@MichaelGFierce: Roche's delivery method 'shuttles' Alzheimer's drugs past blood-brain barrier. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Qiagen and Exosome inked a Dx development deal to create cancer biomarkers. Yesterday's story | Follow @EmilyWFierce

> Boston Scientific ($BSX) CEO Mike Mahoney told a crowd at the J.P. Morgan Healthcare Conference that execs would still plow ahead with renal denervation product development, despite Medtronic's ($MDT) recent clinical trial setback in the space. Story

> California's Varian Medical Systems ($VAR) gained the FDA's 510(k) clearance for an updated version of its ProBeam proton therapy system to treat cancer. Item

> Israel's Medinol has begun two trials of a stent that will use Ariad Pharmaceuticals' ($ARIA) investigational drug ridaforolimus to help prevent narrowing of arteries. The drug previously failed as a cancer treatment. Story

> Intersect ENT, a 2013 Fierce 15 winner backed by Medtronic and others, finalized enrollment in a pivotal trial testing its third implant to treat chronic sinusitis. Story

> Elixir Medical, fresh off a CE mark for its drug-eluting coronary scaffold system, reports that a surgeon at a German hospital has performed the product's first commercial implant. Item

Biotech News

@FierceBiotech: Sanofi launches a new antibiotics effort, teams with Fraunhofer. More | Follow @FierceBiotech

@JohnCFierce: Interesting to see Chelsea Therapeautics win the solid backing of the adcomm. Now back to the FDA, where the weather has been much chillier. Odds on OK? | Follow @JohnCFierce

@DamianFierce: Regeneron, Bayer reach for the old Eylea magic with combo AMD deal. Yesterday's story | Follow @DamianFierce

@EmilyMFierce: Omnibus bill would restore $1B in funding to NIH. Story from FierceBiotech Research | Follow @EmilyMFierce

> Bristol-Myers says it's open to dealmaking in the cancer field. Item

> Aduro's combo cancer vaccine combo posts positive survival benefits. Article

> Billionaire Soon-Shiong ties a $75M knot with Celgene, vows R&D revolution. More

> Chelsea soars after FDA AdCom once again endorses bid to OK Northera. News

Pharma News

@FiercePharma: Novo Nordisk eyes IPO for its IT subsidiary, taps new CFO to lead review. Story | Follow @FiercePharma

@TracyStaton: Best-read FiercePharma Tuesday: Merck CEO: We'll decide on animal health, consumer biz by year-end. Story | Follow @TracyStaton

@EricPFierce: McKesson fails to get EU drug distributor Celesio. Some see the miss as a shame for both. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Drug buyers sue Novo Nordisk over 'wrongful' delays to diabetes generic. Yesterday's story | Follow @CarlyHFierce

> Merck recall depletes supplies of new cholesterol drug. Item

> Lilly CEO Lechleiter predicts big things after its 'most financially challenging year.' Piece

> Glaxo CFO: China sales on the rebound after that big hit from the bribery scandal. Story

Drug Delivery News

> Roche's delivery method 'shuttles' Alzheimer's drugs past the blood-brain barrier. Story

> 'On-off' switch in disguised nanoparticles shows delivery potential. Story

> Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study. Story

> Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019. Item

> Elixir places first DESolve drug-eluting stent in patient. Article

> Amid RNAi buzz, Arcturus touts positive preclinical results. More

Diagnostics News

> J&J will link with a Seattle Dx outfit on a biomarker discovery program. Story

> Ovarian cancer biomarker could predict treatment response and help prevent metastasis. Story

> Microlin Bio files for a $25M IPO to advance cancer Dx and Rx treatments. Story

> Dutch research hospital teams with Probiodrug to assess Alzheimer's biomarker assays. Story

> Dako joins with Merck to concoct cancer treatment companion Dx tests. Article

> Quest seals 3 new Dx development deals. Item